Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eurocept international bv - karglumic acid - hyperammonemia; amino acid metabolism, inborn errors - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - ucedane is indicated in treatment of:hyperammonaemia due to n-acetylglutamate synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

akcea therapeutics ireland limited - volanesorsen sodium - iperlipoproteinemija tip i - oħra li timmodifika ix-xaħmijiet aġenti - waylivra huwa indikat bħala żieda mad-dieta f'pazjenti adulti b'kkonfermat ġenetikament familjali chylomicronemia sindromu (russja) u fil-għoli tar-riskju għall-pankreatite, min-rispons għall-dieta u trigliċeridi li jbaxxu l-terapija kienet inadegwata.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - dacomitinib monohydrate - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - vizimpro, bħala monoterapija, huwa indikat għall-kura tal-ewwel linja ta 'pazjenti adulti b'lokalment avvanzat jew dak metastatiku li mhux ta' ċelluli żgħar kanċer tal-pulmun (nsclc) mar-riċettur tal-fattur tat-tkabbir epidermali (egfr) mutazzjonijiet li jattivaw.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - deferasirox - iron overload; beta-thalassemia - aġenti kelanti tal-ħadid - deferasirox mylan huwa indikat għall-kura ta 'tagħbija żejda kronika tal-ħadid minħabba trasfużjonijiet tad-demm frekwenti (≥7 ml/kg/xahar ta' ċelloli ħomor ippakkjati) f'pazjenti bil-beta talassemija maġġuri ta '6 snin u l-olderthe-trattament tal-eċċess kroniku ta'ħadid minħabba trasfużjonijiet tad-demm meta terapija b'deferoxamine tkun kontra-indikata jew inadegwata f'dawn gruppi ta' pazjenti:f'pazjenti pedjatriċi b'beta-talessimja maġġuri b'tagħbija żejda tal-ħadid minħabba trasfużjonijiet tad-demm frekwenti (≥7 ml/kg/xahar ta ' ċelloli ħomor ippakkjati) b'età minn 2 sa 5 snin,fl-adulti u f'pazjenti pedjatriċi bil-beta talassemija maġġuri b'tagħbija żejda tal-ħadid minħabba trasfużjonijiet tad-demm frekwenti (.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - deferasirox - iron overload; beta-thalassemia - kollha tal-prodotti terapewtiċi l-oħrajn, aġenti kelanti tal-Ħadid - deferasirox qbil huwa indikat għat-trattament tal-eċċess kroniku ta'ħadid minħabba trasfużjonijiet tad-demm frekwenti (≥7 ml/kg/xahar ta 'ċelloli ħomor ippakkjati) f'pazjenti bil-beta talassemija maġġuri ta' 6 snin u akbar fl-età. deferasirox qbil huwa indikat ukoll għat-trattament tal-eċċess kroniku ta'ħadid minħabba trasfużjonijiet tad-demm meta terapija b'deferoxamine tkun kontra-indikata jew inadegwata f'dawn gruppi ta 'pazjenti:f'pazjenti pedjatriċi b'beta-talessimja maġġuri b'tagħbija żejda tal-ħadid minħabba trasfużjonijiet tad-demm frekwenti (≥7 ml/kg/xahar ta' ċelloli ħomor ippakkjati) b'età minn 2 sa 5 snin,f'pazjenti adulti u pedjatriċi li għandhom beta talessimja maġġuri b'tagħbija żejda tal-ħadid minħabba trasfużjonijiet tad-demm frekwenti (.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - limfoma, b-cell - aġenti antineoplastiċi - polivy flimkien ma bendamustine u rituximab huwa indikat għall-kura ta ' pazjenti adulti b'reġgħet tfaċċat/refrattarja b kbira mxerrda-cell lymphoma (dlbcl) li mhumiex kandidati għall-trapjant ta'ċelloli staminali ematopojetiċi. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - aġenti antineoplastiċi - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - aġenti antineoplastiċi - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.